ApoA1 Trial Misses Endpoint, But HDL Hypothesis Still Alive?
ApoA1 infusions in acute MI did not significantly reduce the composite endpoint in the AEGIS-II trial. However, an exploratory analysis suggested benefit at higher LDL levels.
Source: medscape.com